紫杉醇治疗21例晚期肺癌

CLINICAL STUDY OF PACLITAXEL IN TREATMENT OF ADVANCED LUNG CANCER

２１例晚期肺癌病人接受紫杉醇治疗。临床分期ⅢＢ１０例，Ⅳ１１例。化疗方案采用单药紫杉醇组９例，紫杉醇联合应用－ＤＤＰ－ＶＰ１６组１２例，总计３６个疗程。化疗后达ＣＲ１例，ＰＲ４例，ＭＲ４例，有效率２３．８％。紫杉醇的不良反应主要为粒细胞减少２０例次，其中Ⅲ度以上９例次，多为联合用药组，一般发生于用药后ｄ７～８，ｄ１０达最低值，２１ｄ均恢复正常。用Ｇ－ＣＳＦ能减轻粒细胞下降程度。经预防应用抗过敏药物后，无１例发生严重高敏反应。脱发见于每例病人，肌肉关节痛２７例次（７５％）．本药适用于非小细胞肺癌及复发性小细胞肺癌。

Twenty one patients with advanced lung cancer were divided to received paclitaxel( n =9) or cisplatin/etopside/paclitaxel( n =12) for a total course of treatment of 36,with a total response rate of 23.8%.The ADRs of paclitaxel was mainly neutropenia.It occurred in 5.6% in monotherapeutic group and in 44.4% in combined therapeutic group.In general,neutropenia appeared initially on the 7～8th day of chemotherapy,with a nadir at the 10th day and returned to normal at the 21th day.Patients in combined therapeutic group were treated with G CSF.Hypersensitivity recations were mild for all patients were pretreated with corticosteroids,diphenhydramine and H 2 receptor antagonists.Arthralgia and myalgia experienced in 75% patients.Alopecia was observed in all of the patients,other reactions including peripheral neuropathy,nausea,vomiting,diarrhea and mucositis were usually mild.